A compound of formula (l): or a tautomeric or a stereochemically isomeric form, a pharmaceutically acceptable salt or a solvate thereof, wherein: W represents =C(R 4)- or =N-; R 1, R 2, R 3 and R 4 independently represent hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 3-8 cycloalkyl, cyano or -NR x R y; X represents -C (R 6)-, -N(R 14)- or -O-; R 5 represents hydrogen, -CH 2 -R z or oxo, such that when X represents -N(R 14)- or -O-, R 5 represents oxo; R 6 represents hydrogen, -OR 15a, cyano, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkanol, C 3-8 cycloalkyl, halogen, -NR V R W, -CH 2 -NR v R w, -Z-aryl or heterocyclyl, wherein said aryl or heterocyclyl groups may be optionally substituted by one or more oxo, hydroxy, C 1-6 alkanol, -COC 1-6 alkyl (such as -COMe) or -COOC 1-6 alkyl (such as -COOtBu) groups; Z represents a bond or C 1-6 alkylenyl optionally substituted with an oxygen atom; R 7 represents hydrogen, -CH 2 -R z or -OR 15b, such that when X represents -N - or -O-, R 7 represents hydrogen; R 8 represents C 1-6 alkyl, haloC 1-6 alkyl or C 3-8 cycloalkyl; Y represents -C(R 9)= or -N=; R 9, R 10, R 11, R 12 and R 13 independently represent hydrogen, C 1-6 alkyl, C 2-6 alkenyl, hydroxy, C 1-6 alkoxy, C 3-8 cycloalkyl, halogen or haloC 1-6 alkyl or two adjacent groups of said R 9, R 10, R 11, R 12 and R 13 groups may join to form a 5 to 7 membered saturated or unsaturated ring optionally containing one or more heteroatoms selected from O, N or S; R 14 represents hydrogen, C 1-6 alkyl, C 1-6 alkanol or-SO 2 -C 1-6 alkyl; R 15a and R 15b independently represent hydrogen or R 15a and R 15b join together to form a 5 to 7 membered saturated ring system which may be optionally substituted by one or more C 1-6 alkyl groups; R v, R w, R x and R y independently represent hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-8 cycloalkyl, -COC 1-6 alkyl or heterocyclyl, wherein said alkyl groups may be optionally substituted with or more hydroxy, amino or sulfone groups and said heterocyclyl ring may be optionally substituted by one or more oxo, hydroxy, C 1-6 alkanol or -COC 1-6 alkyl groups; and R z represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy or C 1-6 alkanol. W represents =C(R 4)- or =N-; R 1, R 2, R 3 and R 4 independently represent hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 3-8 cycloalkyl, cyano or -NR x R y; X represents -C (R 6)-, -N(R 14)- or -O-; R 5 represents hydrogen, -CH 2 -R z or oxo, such that when X represents -N(R 14)- or -O-, R 5 represents oxo; R 6 represents hydrogen, -OR 15a, cyano, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkanol, C 3-8 cycloalkyl, halogen, -NR V R W, -CH 2 -NR v R w, -Z-aryl or heterocyclyl, wherein said aryl or heterocyclyl groups may be optionally substituted by one or more oxo, hydroxy, C 1-6 alkanol, -COC 1-6 alkyl (such as -COMe) or -COOC 1-6 alkyl (such as -COOtBu) groups; Z represents a bond or C 1-6 alkylenyl optionally substituted with an oxygen atom; R 7 represents hydrogen, -CH 2 -R z or -OR 15b, such that when X represents -N - or -O-, R 7 represents hydrogen; R 8 represents C 1-6 alkyl, haloC 1-6 alkyl or C 3-8 cycloalkyl; Y represents -C(R 9)= or -N=; R 9, R 10, R 11, R 12 and R 13 independently represent hydrogen, C 1-6 alkyl, C 2-6 alkenyl, hydroxy, C 1-6 alkoxy, C 3-8 cycloalkyl, halogen or haloC 1-6 alkyl or two adjacent groups of said R 9, R 10, R 11, R 12 and R 13 groups may join to form a 5 to 7 membered saturated or unsaturated ring optionally containing one or more heteroatoms selected from O, N or S; R 14 represents hydrogen, C 1-6 alkyl, C 1-6 alkanol or-SO 2 -C 1-6 alkyl; R 15a and R 15b independently represent hydrogen or R 15a and R 15b join together to form a 5 to 7 membered saturated ring system which may be optionally substituted by one or more C 1-6 alkyl groups; R v, R w, R x and R y independently represent hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-8 cycloalkyl, -COC 1-6 alkyl or heterocyclyl, wherein said alkyl groups may be optionally substituted with or more hydroxy, amino or sulfone groups and said heterocyclyl ring may be optionally substituted by one or more oxo, hydroxy, C 1-6 alkanol or -COC 1-6 alkyl groups; and R z represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy or C 1-6 alkanol.